Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans.
Bernd Hohenstein, Maite Colin, Christine Foellmer...
https://pubmed.ncbi.nlm.nih.gov/20395257/Actively Recruiting
Led by Military Medical Clinical Center of the Southern Region, Ukraine · Updated on 2026-05-28
82
Participants Needed
2
Research Sites
30 weeks
Total Duration
This research aims to validate the Odesa Criteria 2026 OC26, a new scoring system designed to diagnose autoimmune pancreatitis. The study addresses the challenge of diagnosing autoimmune pancreatitis due to its varied symptoms and overlap with pancreatic cancer and other inflammatory conditions. It evaluates the accuracy and consistency of OC26, which integrates clinical, serological, morphological, and histological information to support diagnosis. The study uses an ambispective observational design, collecting both retrospective and prospective data from patients suspected of having autoimmune pancreatitis. Participants undergo standard clinical, serological, imaging, and histological assessments according to the OC26 scoring system. No experimental treatments or interventions are assigned, as the focus is on observing and validating the diagnostic tool. Participants provide data through routine diagnostic processes, including clinical evaluations, blood tests, imaging, and tissue samples when available. Researchers measure the diagnostic accuracy of OC26 by comparing scores to final clinical diagnoses and assess agreement between observers scoring the domains. Additional analyses include evaluating individual domain performance and determining the best diagnostic score cut-off. The study is conducted up to the completion of baseline diagnostic assessments, with no additional treatment or follow-up required.
CONDITIONS
Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
O
Oleg Dovbenko, MD, PhD
O
Oleg Dovbenko, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Military Medical Clinical Center of the Southern Region, Ukraine
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to baseline diagnostic workup completion
Participants undergo standard clinical, serological, imaging, and histological assessments according to the Odesa Criteria 2026 (OC26) to evaluate suspected autoimmune pancreatitis.
1 to 2 visits depending on diagnostic procedures
Duration - Duration varies based on clinical follow-up
Participants are observed as part of routine clinical practice to monitor diagnostic outcomes and disease progression without assigned intervention.
Visits as per routine clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Bernd Hohenstein, Maite Colin, Christine Foellmer...
https://pubmed.ncbi.nlm.nih.gov/20395257/Christopher J Jones, Cynthia K Larive
https://pubmed.ncbi.nlm.nih.gov/21879299/Military Medical Clinical Center of the Southern Region, Ukraine
Lead Sponsor